Skip to content
OpenCapital
Get started

Organon OGN Dulera — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

BioMarin Pharmaceuticals logo
BMRNALDURAZYME — Total revenues
$36.74M-25.0%
Amgen logo
AMGNUPLIZNA — Total revenues
$262M+188%
Viatris logo
VTRSDymista ® — Net Sales
$37.3M-12.9%
AbbVie logo
ABBVUbrelvy — Net revenues
$339M+41.3%
Biogen logo
BIIBTotal Revenue
$2.48B+1.9%
BioMarin Pharmaceuticals logo
BMRNBRINEURA — Total revenues
$47.1M+16.7%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's dulera — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's dulera — revenue?
Organon (OGN) reported dulera — revenue of $35M in Q1 2026.
How has Organon's dulera — revenue changed year-over-year?
Organon's dulera — revenue decreased by 18.6% year-over-year, from $43M to $35M.
What is the long-term trend for Organon's dulera — revenue?
Over 4 years (2021 to 2025), Organon's dulera — revenue has grown at a -5.3% compound annual growth rate (CAGR), from $190M to $153M.
What does dulera — revenue mean?
This metric represents the total net sales generated from the Dulera product line, a key respiratory therapy within the company's established medicines portfolio. It serves as a primary indicator of the product's market demand, competitive positioning, and lifecycle maturity. Tracking these revenues helps investors assess the contribution of this specific asset to the company's overall top-line performance and its resilience against generic competition.